Navigation Links
Geisinger research: Antimalarial drug prevents diabetes in arthritis patients
Date:10/28/2008

DANVILLE, PA - The use of an antimalarial medication may prevent the onset of diabetes in patients with rheumatoid arthritis, new Geisinger research shows.

Researchers examined the records of 2,093 Geisinger patients who received treatment for rheumatoid arthritis from 2000 to 2008. The study looked at, among other things, use of the medication hydroxychloroquine (HCQ) and the development of new cases of diabetes in these patients.

HCQ was developed to treat malaria but it has also been used to treat rheumatoid arthritis and other autoimmune diseases.

In patients with rheumatoid arthritis, use of HCQ was associated with a 53 percent reduction in the development of new cases of diabetes, the study found.

"Given the relative safety and low cost of this generic drug, HCQ may be useful in preventing diabetes in other high risk groups," said lead study investigator and Geisinger rheumatologist Androniki Bili, MD, MPH.

Researchers don't know how exactly HCQ prevents diabetes onset but it's suspected that HCQ improves glucose tolerance.

Dr. Bili presented the study's findings Monday at the American College of Rheumatology Annual Scientific Meeting in San Francisco.

About 23.6 million Americans have diabetes, while 1.3 million have rheumatoid arthritis.

People with rheumatoid arthritis are at increased risk for diabetes due to more sedentary lifestyle, chronic inflammation and use of steroid medications that can cause weight gain.

"We should revisit HCQ in the treatment of rheumatoid arthritis because, in addition to its disease-modifying properties, it might prevent the development of diabetes in this high risk group," Dr. Bili said.


'/>"/>

Contact: Justin Walden
jawalden@geisinger.edu
570-271-8083
Geisinger Health System
Source:Eurekalert

Page: 1

Related biology news :

1. Geisinger piloting innovative laboratory specimen processing instrument
2. Geisinger study: Inflammatory disease causes blindness
3. Robotics research: Enhancing the lives of people with disabilities
4. Advances in the field of schizophrenia research: New genetic factors identified
5. New research: Fruit juice consumption not related to overweight in children
6. Paradigm shift in Alzheimerss research: new treatments
7. Resveratrol prevents fat accumulation in livers of alcoholic mice
8. Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
9. Chemical compound prevents cancer in lab
10. A compound extracted from olives inhibits cancer cells growth and prevents their appearance
11. Device prevents potential errors in childrens medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... Feb. 3, 2016   ViaCyte, Inc ., ... first pluripotent stem cell-derived islet replacement therapy for ... development, today announced that ViaCyte and Janssen Biotech, ... Johnson & Johnson, have agreed to consolidate the ... The agreement provides ViaCyte with an exclusive license ...
(Date:2/3/2016)... , Feb. 3, 2016  With the growing ... cliff that is underway, therapies such as monoclonal ... a whole host of indications are in high ... in the development and production of these therapeutics. ... quality and high costs, novel approaches and novel ...
(Date:2/3/2016)... 3, 2016 Harvard Apparatus Regenerative Technology, ... developing bioengineered organ implants for life-threatening conditions of ... CEO Jim McGorry , will present at ... on Tuesday, February 9, 2016 at 8:00 am ... . HART,s presentation will be webcast live and ...
(Date:2/3/2016)... ... 03, 2016 , ... Aerocom, a world-leading supplier of pneumatic ... American healthcare market. , Aerocom Healthcare, LLC will be based in Denver, Colo., ... new pneumatic tube systems or expand existing systems within the U.S. and Canada. ...
Breaking Biology Technology: